The "Dok-1 Max" case, which has been linked to the tragic deaths of 65 children in Uzbekistan, is currently undergoing a criminal trial at the Tashkent City Court. Indian Marion Biotech Pvt. Ltd. is the manufacturer of the controversial Dok-1 Max syrup, which is believed to have caused these fatalities. In a startling development, one of the defendants, G.B., who serves as the head of the laboratory "Quality Control and Standardization of Medicines" at the "State Center for Expertise and Standardization of Medicines, Medical Devices, and Medical Equipment," revealed critical information during a recent court session, Daryo reports.
Defendant's Testimony on Additional Drugs
During a recent court session, G.B., one of the defendants, came forward with significant revelations. G.B. explained that officials from Indian Marion Biotech Pvt. Ltd. had sought registration for four additional drugs containing toxic substances similar to those found in the notorious "Dok-1 Max" syrup. These toxic substances included ethylene glycol and diethylene glycol. The drugs in question were identified as follows:
- "Tarirex," which was later registered under the name "Kuraraks."
- "Kuyurazit," a tablet medicine.
- "Tramjoyn," another tablet medicine.
- "Razinoks," a tablet medicine.
The defendant stated that these drugs were entered into an electronic database called "Dashboard," and efforts were made to address the identified deficiencies. Importantly, these drugs have not yet been made available for sale in Uzbekistani pharmacies, shedding light on a potential hazard that was prevented from reaching the public.
Media Controversy in Court Proceedings
The trial of the "Dok-1 Max" case, which commenced on August 11, 2023, is being conducted as an open court session. However, there has been growing controversy surrounding media involvement in the trial proceedings.
Defense lawyers for the defendants have repeatedly raised objections to the activities of the mass media, alleging that sensitive court information is being released to the public prematurely. Specifically, they accused "Kun.uz" and "Qalampir.uz" publications of not adhering to the principle of the presumption of innocence.
Furthermore, they accused "Gazeta.uz" of providing online coverage of court proceedings while restricting their own activities. Subsequently, representatives of "Gazeta.uz" chose not to participate in the court sessions.
During a recent court session held on September 8, lawyer Sobirov, representing one of the defendants, accused the internet publication "Daryo" of publishing court information publicly and revealing sensitive details provided by insiders. In response, Sobirov submitted a petition to the court panel, requesting the expulsion of journalists from "Daryo" and other mass media representatives who have been attending the court proceedings.
In its defense, "Daryo" publication stated that the information it released was sourced from the defendants who spoke in court. The publication also indicated that additional compelling information had emerged during the question-and-answer sessions involving defendants and lawyers, which it refrained from disclosing to avoid interfering with the court's ongoing investigation.
The "Dok-1 Max" case remains a high-profile and emotionally charged trial in Uzbekistan. The recent revelations regarding the attempted registration of drugs containing toxic substances have added a new dimension to the case.
Earlier Daryo reported that one of the defendants, identified as S.S., denied the charges against him.
Follow Daryo's official Instagram and Twitter pages to keep current on world news.
Comments (0)